What is the 13F Pro Quality Score for PALI?

13F Pro ranks PALISADE BIO, INC. (PALI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PALI's current score at https://13fpro.ai/research/PALI (free sign-up required for the full ranking).

Which hedge funds own the most PALI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PALI include B Group,, JANUS HENDERSON GROUP PLC, Octagon Capital Advisors. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/PALI as soon as new 13F filings post.

Where does 13F Pro source PALI data?

All PALISADE BIO, INC. fundamentals and ownership data come directly from SEC EDGAR. PALISADE BIO, INC. files with the SEC under CIK 1357459. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PALI in?

PALISADE BIO, INC. (PALI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PALI research updated on 13F Pro?

PALI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PALISADE BIO, INC.(PALI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1357459 PALI stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.7M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PALI Stock Analysis & AI Quality Score

AI stock analysis and institutional research for PALISADE BIO, INC. (PALI), a Healthcare sector company. PALI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.7m in revenue. Based on the latest XBRL financial filings (Q1 2026), PALISADE BIO, INC. reports net income of $-9.6M, free cash flow of $-3.9M. Top institutional holders of PALI by reported 13-F value include B Group,, JANUS HENDERSON GROUP PLC, Octagon Capital Advisors, based on the most recent SEC filings. PALI trades on the Nasdaq exchange and files with the SEC under CIK 1357459. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PALI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PALISADE BIO, INC. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-9.6M

Free Cash Flow

Q1 2026

$-3.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2024

FY21 —FY22 $0.00FY23 $250.0KFY24 $0.00

Net Income

-17.4% YoY

$-14.4MFY 2024

FY21 $-26.6MFY22 $-14.3MFY23 $-12.3MFY24 $-14.4M

Operating Income

-13.7% YoY

$-14.9MFY 2024

FY21 $-41.9MFY22 $-15.7MFY23 $-13.1MFY24 $-14.9M

EPS (Diluted)

+62.3% YoY

$-5.09FY 2024

FY21 $-169.74FY22 $-16.53FY23 $-13.51FY24 $-5.09

Total Assets

-22.6% YoY

$10.9MFY 2024

FY21 $12.5MFY22 $15.8MFY23 $14.1MFY24 $10.9M

Total Debt

—FY 2024

FY21 $174.0KFY22 —FY23 —FY24 —

Op. Cash Flow

-9.5% YoY

$-12.2MFY 2024

FY21 $-14.8MFY22 $-13.4MFY23 $-11.1MFY24 $-12.2M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$0.00 -100.0%	$250.0K	$0.00	—	$13.5K -12.2%	$15.4K
Net Income	$-14.4M -17.4%	$-12.3M +13.7%	$-14.3M +46.4%	$-26.6M -157.9%	$-10.3M -23.6%	$-8.4M
Operating Income	$-14.9M -13.7%	$-13.1M +16.9%	$-15.7M +62.4%	$-41.9M -350.2%	$-9.3M -7.7%	$-8.6M
EPS (Diluted)	$-5.09 +62.3%	$-13.51 +18.3%	$-16.53 +90.3%	$-169.74 -4462.9%	$-3.72	—
Total Assets	$10.9M -22.6%	$14.1M -10.9%	$15.8M +26.0%	$12.5M +314.4%	$3.0M -54.1%	$6.6M
Total Debt	—	—	—	$174.0K -92.0%	$2.2M	—
Operating Cash Flow	$-12.2M -9.5%	$-11.1M +16.7%	$-13.4M +9.6%	$-14.8M -209.8%	$-4.8M +34.3%	$-7.3M

AI Insight: PALI Financial Trends

Palisade remains pre-revenue with accelerating losses post-financing; equity injection in Q4 2025 paused cash burn but operating losses widened.

• Equity surged from $3M in Q3 2025 to $129M in Q4 2025, indicating major financing event that stabilized balance sheet.

• Operating losses expanded: Q4 2025 op income of -$10M and Q1 2026 of -$11M versus -$2M to -$4M range prior quarters.

• Net losses in Q4 2025 and Q1 2026 both at -$9M to -$10M, highest in dataset; company burning equity raised in Q4 2025.

⚠ Operating cash outflow worsened to -$4M in Q1 2026 from -$2M to -$3M pre-financing; sustainability of cash runway unclear.

⚠ Zero revenue across all periods; no commercialization timeline evident. Company remains pure R&D burn story.

AI Insight: PALI Ratio Trends

Palisade Bio's negative returns deteriorated sharply in Q4 2025–Q1 2026 after improving through mid-2025, signaling intensifying cash burn or operational headwinds.

• ROE plummeted from -27.5% in Q4 2025 to -30.1% in Q1 2026; ROA fell to -28.8%, reflecting deepening losses relative to equity and assets.

• ROIC deteriorated to -33.8% in Q1 2026 from -30.9% in Q4 2025, a four-quarter low, indicating worsening capital efficiency.

• TTM ROE of -19.0% and ROIC of -20.8% show some improvement versus Q1 2026 quarter-only metrics, suggesting recent quarters were disproportionately weak.

⚠ All profitability metrics remain deeply negative with no near-term path to breakeven visible; unsustainable burn rate threatens runway.

⚠ Data gaps in OpMargin, NPM, and D/E across all periods prevent assessment of leverage, revenue quality, or operational structure.

Get alerted when PALI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PALISADE BIO, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PALI

B Group, Inc.
$20.0M11,414,285 sh
JANUS HENDERSON GROUP PLC
$18.8M10,689,452 sh
Octagon Capital Advisors LP
$18.0M10,276,317 sh
PERCEPTIVE ADVISORS LLC
$15.6M8,928,149 sh
AMERIPRISE FINANCIAL INC
$15.2M8,711,385 sh
Commodore Capital LP
$12.6M7,181,062 sh
RA CAPITAL MANAGEMENT, L.P.
$12.5M7,124,116 sh
FRANKLIN RESOURCES INC
$10.1M5,785,189 sh
GOLDMAN SACHS GROUP INC
$9.4M5,373,951 sh
Eversept Partners, LP
$8.7M4,987,499 sh

Fund	Value	Shares
B Group, Inc.	$20.0M	11,414,285
JANUS HENDERSON GROUP PLC	$18.8M	10,689,452
Octagon Capital Advisors LP	$18.0M	10,276,317
PERCEPTIVE ADVISORS LLC	$15.6M	8,928,149
AMERIPRISE FINANCIAL INC	$15.2M	8,711,385
Commodore Capital LP	$12.6M	7,181,062
RA CAPITAL MANAGEMENT, L.P.	$12.5M	7,124,116
FRANKLIN RESOURCES INC	$10.1M	5,785,189
GOLDMAN SACHS GROUP INC	$9.4M	5,373,951
Eversept Partners, LP	$8.7M	4,987,499

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PALI on your watchlist

Track score changes the day PALISADE BIO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PALI a good stock to buy?

13F Pro's AI-powered analysis of PALISADE BIO, INC. (PALI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PALI are available on the PALI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PALI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PALI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PALISADE BIO, INC.'s investment landscape.